Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT05595863 |
| Other study ID # |
123glioma |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
November 2022 |
| Est. completion date |
December 2023 |
Study information
| Verified date |
October 2022 |
| Source |
Assiut University |
| Contact |
Radwa gaber Elsaady |
| Phone |
+201006414845 |
| Email |
noooor2.2010[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Major advances in cancer genetics over the past decade have revealed that the genes encoding
IDHs are frequently mutated in a variety of human malignancies, including gliomas.Pentavalent
99mTc dimercaptosuccinic acid (99mTc (V) DMSA), is a nonspecific tumor targeting SPECT
radiotracer, that has been used for imaging of various tumors including lung and breast
carcinoma. However, to date, scarce reports discussed the utility of DMSA-V in patients with
glioma.SPECT has the advantages of being widely available and not expensive. Multiple SPECT
tracers have been explored. Of them Thallium-201 and 99 mTc-MIBI are, possibly, the most
extensively discussed.
Description:
Every year, nearly100,000 people worldwide are diagnosed as having brain gliomas. Although it
comprises <1% of all newly diagnosed cancers, brain glioma is associated with substantial
mortality and morbidity. Gliomas are intrinsic brain tumors that originate from neuroglial
progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy,
have achieved limited improvements in the prognosis of glioma patients.
Radiation therapy to the brain may lead to postradiation injury which typically occurs within
the first 3 to 12 months after radiotherapy but it was reported up to several years and even
decades later. The clinical picture of radiation necrosis (RN) is variable and may include
seizures, headache, personality changes, and neurologic deficits. These symptoms mimic tumor
recurrence and differentiation between the two entities clinically or even by conventional
radiological modalities is difficult but is necessary because the two conditions have
different treatment modalities and prognosis.
SPECT has the advantages of being widely available and not expensive. Multiple SPECT tracers
have been explored. Of them Thallium-201 and 99 mTc-MIBI are, possibly, the most extensively
discussed. The main disadvantage of 201Tl is the lower spatial resolution, relatively large
radiation dose, and the reported high false positive results. Normal uptake of MIBI in the
choroid plexus may be confounding for assessing tumors around the ventricles.
Pentavalent 99mTc dimercaptosuccinic acid (99mTc (V) DMSA), is a nonspecific tumor targeting
SPECT radiotracer, that has been used for imaging of various tumors including lung and breast
carcinoma. However, to date, scarce reports discussed the utility of DMSA-V in patients with
glioma.
Isocitrate dehydrogenase (IDH) enzymes, of which there are three isoforms, are essential
enzymes that participate in several major metabolic processes, such as the Krebs cycle,
glutamine metabolism, lipogenesis and redox regulation.
Major advances in cancer genetics over the past decade have revealed that the genes encoding
IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute
myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma.
